Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific
antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on
the aim of reducing or eliminating DSA, some proposed different therapeutic regimens for cAMR
treatment. All of these protocols were derived from previous experience using acute
antibody-mediated rejection and desensitization protocols, and mainly consisted of steroids,
plasma exchange (PE), IVIG and RTX in various modalities. More recently, bortezomib was also
proposed.To evaluate the role of a therapeutic regimen with plasma exchange, intravenous
immunoglobulins and rituximab with or without Bortezomib in chronic-active antibody-mediated
rejection (cAMR) settings this study designed.